Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.
Continues to deliver sequential growth in covered lives, prescribing physicians and FSS facilities Company to host conference call and webcast today, May 14 , at 4:30pm ET BASKING RIDGE, N.J. , May 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , May 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report first quarter ended March 31, 2019 financial results after the close of the
gammaCore™ chosen by NHS England to be funded by the Innovation and Technology Payment Program (ITP) for the period of April 2019 to April 2020 to support adoption in the U.K. LONDON and BASKING RIDGE, N.J. , May 06, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a